Received Feb 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | AMVB030A | SC |
Menveo vaccine subcutaneously instead of intramuscularly; This non-serious case was reported by a other health professional via call center representative and described the occurrence of intramuscular formulation administered by other route in a 21-year-old male patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVB030A, expiry date 30-APR-2025) for prophylaxis. On 29-JAN-2025, the patient received Menveo (subcutaneous). On 29-JAN-2025, an unknown time after receiving Menveo, the patient experienced intramuscular formulation administered by other route (Verbatim: Menveo vaccine subcutaneously instead of intramuscularly). The outcome of the intramuscular formulation administered by other route was unknown. Additional Information: GSK Receipt Date: 31-JAN-2025 Pharmacy technician stated that a patient was administered on 29 January 2025 with a Menveo 2-vial vaccine subcutaneously instead of intramuscularly which led to Intramuscular formulation administered by other route. Caller did not know if it was the first dose of a meningococcal vaccine for this patient.